(NASDAQ: ALNY) Alnylam Pharmaceuticals's forecast annual revenue growth rate of 14.84% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Alnylam Pharmaceuticals's revenue in 2024 is $2,003,335,000.On average, 12 Wall Street analysts forecast ALNY's revenue for 2024 to be $235,340,482,805, with the lowest ALNY revenue forecast at $224,821,426,546, and the highest ALNY revenue forecast at $246,005,004,608. On average, 12 Wall Street analysts forecast ALNY's revenue for 2025 to be $278,684,534,929, with the lowest ALNY revenue forecast at $238,272,562,219, and the highest ALNY revenue forecast at $319,783,863,962.
In 2026, ALNY is forecast to generate $402,309,756,256 in revenue, with the lowest revenue forecast at $324,820,766,562 and the highest revenue forecast at $573,690,809,941.